PBLA Share Price Performance
US$0.16
-0.22 (-58.45%)
Price US$0.16
Share PriceUS$0.16
PBLA Community Narratives
There are no narratives available yet.
Recent PBLA News & Updates
No updates
Panbela Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -7.63
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -35.2%
Panbela Therapeutics, Inc. Competitors
About PBLA
- Founded
- 2011
- Employees
- 8
- CEO
- WebsiteView website
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading